Reviewing Taysha Gene Therapies (TSHA) and Its Competitors

Taysha Gene Therapies (NASDAQ:TSHA) is one of 847 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Taysha Gene Therapies to similar businesses based on the strength of its valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Risk & Volatility

Taysha Gene Therapies has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies’ rivals have a beta of 1.07, indicating that their average stock price is 7% more volatile than the S&P 500.

Earnings & Valuation

This table compares Taysha Gene Therapies and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Taysha Gene Therapies	$9.77 million	-$109.00 million	-10.08
Taysha Gene Therapies Competitors	$695.89 million	$9.64 million	-10.06

Taysha Gene Therapies’ rivals have higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Taysha Gene Therapies and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1	0	12	2	3.00
Taysha Gene Therapies Competitors	9772	15006	45336	1579	2.54

Taysha Gene Therapies currently has a consensus target price of $12.77, suggesting a potential upside of 201.52%. As a group, “Biotechnology” companies have a potential upside of 95.26%. Given Taysha Gene Therapies’ stronger consensus rating and higher probable upside, research analysts clearly believe Taysha Gene Therapies is more favorable than its rivals.

Profitability

This table compares Taysha Gene Therapies and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Taysha Gene Therapies Competitors	-9,046.42%	-198.98%	-30.68%

Summary

Taysha Gene Therapies beats its rivals on 8 of the 13 factors compared.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.